Stock Analiz

Emergent BioSolutions Inc. EBS

Biotechnology: Pharmaceutical Preparations · IPO 2006 · data as of November 13, 2026

$5.79Market cap $298M
Open the interactive analysis →

Emergent BioSolutions Inc. (EBS) is a healthcare company listed in the US with a market value of about $298M. In the twelve months to September 30, 2026 it had revenue of $649M and net income of -$261M, a net margin of -40.2%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).

Key numbers: a price to free cash flow of 1.6, 5-year revenue growth of -14% a year, a 5-year average ROIC of -7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 94% above the current price.

About Emergent BioSolutions

Emergent BioSolutions is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2006. Revenue went from $450M in 2014 to $743M in 2025, growth of about 4.7% a year. It was profitable in 7 of the last 10 years in our data. Its share count rose by 13% over three years (dilution for shareholders). It spends 7% of revenue on research and development.

Score: 1.4 / 5

Value2/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns1/5

Checks passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • Positive free cash flow
  • Debt below 3 years of free cash flow
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF1.6
P/S0.5
P/B1.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield63.3%
Shareholder yield8.4%
Intrinsic value vs. price+94%

Growth and quality

Revenue growth (1 yr)-28.8%
Revenue growth (5 yrs, per year)-14.0%
EPS growth (5 yrs, per year)-30.4%
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-18.0%
ROIC (5-yr avg.)-7.0%
Profitable years (of last 10)7
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$649M$743M$1.0B$1.0B$1.1B$1.8B$1.6B$1.1B$782M$561M$489M
Net income-$261M$53M-$191M-$760M-$212M$220M$306M$54M$63M$83M$52M
Free cash flow$188M$157M$36M-$258M-$150M$96M$395M$101M-$30M$153M-$22M
EPS (diluted)$-5.02$0.93$-3.60$-14.85$-4.22$4.06$5.68$1.04$1.22$1.71$1.13
Net margin-40.2%7.1%-18.3%-72.5%-18.9%12.4%19.4%4.9%8.0%14.7%10.6%
ROIC—5.7%-7.2%-37.4%-5.8%9.9%13.7%4.1%3.8%9.3%7.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 2 analysts is $10.00, 73% above the current price; targets range from $10.00 to $10.00; the consensus rating is “Buy”; expected EPS is $0.29 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Emergent BioSolutions stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 94% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Emergent BioSolutions pay a dividend?

Not currently.

Is Emergent BioSolutions a good stock to buy?

We do not give buy or sell advice. Emergent BioSolutions scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.